By co-activating metabolic deprivation (via SREBF2 inhibition), loss of invasive potential (via TGF-β suppression), and stress/CTL-induced apoptosis (via HSPA1/CDKN1A), these agents generate a lethal epigenetic storm that suppresses tumor growth, metastasis, and therapy resistance. Here, SREBF2 is linked to neoplasm.